The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. “Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets," said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
